Hampson LV - Search Results

1

Bayesian survival analysis in clinical trials: What methods are used in practice?

Brard C, Le Teuff G, Le Deley MC, Hampson LV. Brard C, et al. Among authors: hampson lv. Clin Trials. 2017 Feb;14(1):78-87. doi: 10.1177/1740774516673362. Epub 2016 Oct 11. Clin Trials. 2017. PMID: 27729499 Review.

2

A Bayesian approach for dose-escalation in a Phase I clinical trial incorporating pharmacodynamic endpoints.

Whitehead J, Zhou Y, Hampson L, Ledent E, Pereira A. Whitehead J, et al. J Biopharm Stat. 2007;17(6):1117-29. doi: 10.1080/10543400701645165. J Biopharm Stat. 2007. PMID: 18027220

3

Incorporating prognostic factors into causal estimators: a comparison of methods for randomised controlled trials with a time-to-event outcome.

Hampson LV, Metcalfe C. Hampson LV, et al. Stat Med. 2012 Nov 20;31(26):3073-88. doi: 10.1002/sim.5411. Epub 2012 Jun 19. Stat Med. 2012. PMID: 22714785

4

Cost-utility analysis conducted alongside randomized controlled trials: are economic end points considered in sample size calculations and does it matter?

Hollingworth W, McKell-Redwood D, Hampson L, Metcalfe C. Hollingworth W, et al. Clin Trials. 2013 Feb;10(1):43-53. doi: 10.1177/1740774512465358. Epub 2012 Dec 11. Clin Trials. 2013. PMID: 23231969

5

Bridging the gap: a review of dose investigations in paediatric investigation plans.

Hampson LV, Herold R, Posch M, Saperia J, Whitehead A. Hampson LV, et al. Br J Clin Pharmacol. 2014 Oct;78(4):898-907. doi: 10.1111/bcp.12402. Br J Clin Pharmacol. 2014. PMID: 24720849 Free PMC article.

6

Bayesian methods for the design and interpretation of clinical trials in very rare diseases.

Hampson LV, Whitehead J, Eleftheriou D, Brogan P. Hampson LV, et al. Stat Med. 2014 Oct 30;33(24):4186-201. doi: 10.1002/sim.6225. Epub 2014 Jun 23. Stat Med. 2014. PMID: 24957522 Free PMC article.

7

Optimizing the data combination rule for seamless phase II/III clinical trials.

Hampson LV, Jennison C. Hampson LV, et al. Stat Med. 2015 Jan 15;34(1):39-58. doi: 10.1002/sim.6316. Epub 2014 Oct 15. Stat Med. 2015. PMID: 25315892 Free PMC article.

8

Designing multi-arm multi-stage clinical trials using a risk-benefit criterion for treatment selection.

Jaki T, Hampson LV. Jaki T, et al. Among authors: hampson lv. Stat Med. 2016 Feb 20;35(4):522-33. doi: 10.1002/sim.6760. Epub 2015 Oct 12. Stat Med. 2016. PMID: 26456537 Free PMC article.

9

Extrapolation of efficacy and other data to support the development of new medicines for children: A systematic review of methods.

Wadsworth I, Hampson LV, Jaki T. Wadsworth I, et al. Among authors: hampson lv. Stat Methods Med Res. 2018 Feb;27(2):398-413. doi: 10.1177/0962280216631359. Epub 2016 Mar 17. Stat Methods Med Res. 2018. PMID: 26994211

10

Choosing the target difference ('effect size') for a randomised controlled trial - DELTA² guidance protocol.

Cook JA, Julious SA, Sones W, Rothwell JC, Ramsay CR, Hampson LV, Emsley R, Walters SJ, Hewitt C, Bland M, Fergusson DA, Berlin JA, Altman D, Vale LD. Cook JA, et al. Among authors: hampson lv. Trials. 2017 Jun 12;18(1):271. doi: 10.1186/s13063-017-1969-5. Trials. 2017. PMID: 28606102 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

50 results

Search Page

Filters